- A study result is a group finding tied to a named product, regimen, population, comparator, endpoint, and follow-up period.
- ClinicalTrials.gov, PubMed, FDA pages, and company announcements answer different evidence questions.
- Approved-product evidence and compounded-product questions must remain separate.
- A research summary should state what the source cannot prove, not only what the headline says.
Start with the question
Before reading a percentage or a headline, write down the question. Are you asking whether a product was reviewed by FDA, whether a trial was registered, whether a group changed over time, or whether a prescription may be appropriate? Those are different questions and require different sources.
Check the source type
An FDA page is the right place for regulatory status and statutory boundaries. A PubMed record can identify a peer-reviewed study and its methods. A ClinicalTrials.gov record can show a registered study’s design and status. A company announcement may describe preliminary information but is not a substitute for a full peer-reviewed publication or FDA review.
- Regulatory question: start with the FDA source and read its scope.
- Study question: read the abstract and methods, not only a social post or summary.
- Registry question: check the study record, update date, and posted results.
- Care question: ask a licensed healthcare provider about your own prescription context.
Read the study context
For a named study, identify the product, regimen, population, comparator, endpoint, duration, and funding. SURMOUNT-5 (PubMed 40353578), for example, studied maximum tolerated doses of approved tirzepatide and semaglutide in 751 adults with obesity without type 2 diabetes for 72 weeks. That context belongs with the result.
A group average is not a personal forecast. A study of an approved product does not establish an outcome for a compounded preparation. A registry entry without posted results does not establish efficacy or safety outcomes.
Name what the source cannot prove
FDA’s information on unapproved GLP-1 drugs explains that compounded products are not reviewed by FDA for safety, effectiveness, or quality before marketing. FDA’s 503A and 503B materials describe statutory pathways; those categories are not a product approval or safety ranking. ClinicalTrials.gov records NCT06662383 and NCT07232719 provide investigational-study context, not a shortcut to an outcome claim.
Kind MD is a telehealth platform that connects eligible patients with licensed healthcare providers who may prescribe compounded semaglutide or tirzepatide when clinically appropriate. This educational page does not turn study evidence into a promise or a prescribing direction.
Have a study or prescription question?
Bring the source and your questions to a licensed provider.
Take the Free Quiz →